CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Teclistamab 用于多发性骨髓瘤：首创双特异性抗体的临床见解与实践考量
英文原题：Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
查看英文原题
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Teclistamab是一种BCMAxCD3双特异性抗体，是首个获批用于治疗复发/难治性多发性骨髓瘤的药物。鉴于其在经过大量预处理的患者中具有显著疗效，且相较于靶向BCMA的CAR-T 细胞更易获得，teclistamab必将成为复发/难治性多发性骨髓瘤治疗的基石。Teclistamab具有一系列值得注意的不良反应，包括细胞因子释放综合征（CRS）、感染和神经毒性，医务人员必须采取独特的预防措施和预防性干预。本文综述了促使teclistamab获批的临床前和临床数据、重要的患者选择考量、CRS及其他副作用的管理策略，以及双特异性抗体治疗多发性骨髓瘤的未来前景。
展开英文摘要原文
Teclistamab is a BCMAxCD3 bispecific antibody, the first approved for the treatment of relapsed or refractory multiple myeloma. Given its impressive efficacy in heavily pretreated patients and better accessibility compared to BCMA-directed CAR T cells, teclistamab is sure to become a staple of relapsed/refractory multiple myeloma therapy. Teclistamab carries a set of notable adverse effects including cytokine release syndrome (CRS), infections, and neurotoxicity for which providers must take unique precautions and prophylactic measures.
Here, we review the preclinical and clinical data, which led to teclistamab's approval, important patient selection considerations, strategies for managing CRS and other side effects, and finally the future of bispecific antibody therapy in multiple myeloma.
论文信息
- 作者
- Pan D、Richter J
- 单位
- Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.United States
- 文献类型
- 综述
- 期刊
- Cancer management and research2023
- 原文标识
- PubMed 37497430 · DOI 10.2147/CMAR.S372237
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →